Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 20,866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Completed Phase 2 Interventional

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

NCT01112423
View directory record Official record
Conditions
Dyslipidemia
Interventions
BMS-823778, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Lenexa, Kansas • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Phase 1 Interventional

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

NCT00049023
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
90Y-DOTA-tyr3-OCTREOTIDE
Radiation
Lead sponsor
O'Dorisio, M S
Other
Eligibility
2 Years to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Not applicable Interventional

Vascular Changes of Rotator Cuff Repair Augmented With a Whole Blood Fibrin Clot

NCT03577379
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Whole Blood Fibrin Clot
Other
Lead sponsor
Santa Barbara Cottage Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 17, 2026, 12:06 PM EDT
Recruiting Not applicable Interventional

Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)

NCT03588286
View directory record Official record
Conditions
Sudden Cardiac Death
Interventions
Electrophysiology study (EPS), Standard Care, Cardiac Magnetic Resonance (CMR)
Procedure · Other
Lead sponsor
Western Sydney Local Health District
Other
Eligibility
18 Years to 85 Years
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Not applicable Interventional

Utilizing Blood Volume Measurements in the Treatment of Heart Failure Patients

NCT00861770
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Ultrafiltration, Ultrafiltration using BVM
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 17, 2026, 12:06 PM EDT
Completed No phase listed Observational

Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)

NCT01393483
View directory record Official record
Conditions
Esophageal Cancer, Adenocarcinoma
Interventions
serum and tissue mesothelin
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Not applicable Interventional Results available

DDBT Adapted Problem Solving Treatment for Primary Care

NCT03514394
View directory record Official record
Conditions
Depression, PTSD
Interventions
Usual Care, Modified Behavioral Activation (Task Sharing)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Hardin, Montana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 17, 2026, 12:06 PM EDT
Recruiting No phase listed Observational

IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures

NCT04842266
View directory record Official record
Conditions
Cancer Metastatic, Trauma, Pathologic Fracture
Interventions
IlluminOss pelvic implant for oncologic indication, IlluminOss pelvic implant for geriatric trauma indication
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 17, 2026, 12:06 PM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

NCT01080222
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
telaprevir, VX-222, ribavirin, peginterferon-alfa-2a
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

NCT01642602
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
35
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Phase 1Phase 2 Interventional

Virtual Reality (VR) Therapy for Post-Traumatic Stress Disorder (PTSD)

NCT00992953
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Treatment as Usual, Virtual Reality Exposure with Stimulus Control
Behavioral
Lead sponsor
Office of Naval Research (ONR)
Federal
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Camp Pendlton, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2009 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Phase 2 Interventional Results available

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

NCT01490723
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging, 90Y IbritumomabTiuxetan, Fludarabine, Bendamustine, Thymoglobulin, Tacrolimus, Methotrexate, Mycophenolate, G-CSF, Stem Cell Transplantation
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Phase 2 Interventional

Targeting HIV Risk Behaviors in Juvenile Drug Court-Involved Youth

NCT01511380
View directory record Official record
Conditions
Substance Use, Sexual Risk Behaviors
Interventions
Risk Reduction Therapy for Adolescents, Usual services
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

NCT01246479
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
Blood draw, IC51 has given in the parent study IC51-322
Procedure · Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
9 Months to 20 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 17, 2026, 12:06 PM EDT
Recruiting Not applicable Interventional

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

NCT06896162
View directory record Official record
Conditions
Solid Tumor Malignancies, Metastatic Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Bladder Cancer
Interventions
Expert Review, Blood or tissue samples collection., The Precision Oncology Navigation
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

NCT02834403
View directory record Official record
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
L-NMMA, Docetaxel, Amlodipine, Pegfilgrastim, Enteric-coated aspirin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 17, 2026, 12:06 PM EDT
Recruiting Phase 2 Interventional

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

NCT06510361
View directory record Official record
Conditions
Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
Interventions
Epcoritamab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 17, 2026, 12:06 PM EDT
Completed No phase listed Observational

Octagam 5% Versus Comparator Post Marketing Trial

NCT01859754
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
Octagam 5%, Other marketed IVIG product
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
27
States / cities
Granada Hills, California • Irvine, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 17, 2026, 12:06 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Alcohol and Bariatric Surgery

NCT02766322
View directory record Official record
Conditions
Obesity
Interventions
Oral Alcohol challenge test Alcohol visit first, Oral Alcohol challenge test Placebo visit first, Intravenous Alcohol Challenge Test (Clamp), Intravenous Alcohol Self-administration Test
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Not applicable Interventional

Impact of a Patient Decision Aid for Treatment of Aortic Stenosis

NCT04103931
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
"Treatment Choices for Aortic Stenosis" Decision Aid
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Phase 2 Interventional Results available

Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease

NCT01963845
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Phase 2 Interventional

Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder

NCT03418623
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
GET73, Placebo
Drug · Other
Lead sponsor
Laboratorio Farmaceutico Ct S.r.l.
Industry
Eligibility
21 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 17, 2026, 12:06 PM EDT
Not listed Phase 3 Interventional

Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer

NCT00246727
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Selected Vegetable and Herb Mix
Drug
Lead sponsor
Sun Farm Corporation
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced Oct 17, 2026, 12:06 PM EDT
Completed Phase 1 Interventional

Effect of Different Skin Creams on TEWL

NCT03663673
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
EpiCeram, Aveeno Daily Moisturising Sheer Hydration Lotion®
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 40 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 17, 2026, 12:06 PM EDT